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Abstract With high survival rates for chronic myeloid leuke-
mia (CML) patients treated with BCR-ABL1 tyrosine kinase
inhibitors (TKIs), emerging consequences, such as arterial
ischemic events, require consideration when evaluating treat-
ment options. Cardiovascular ischemic event incidence in
clinical trials was evaluated in 2712 dasatinib-treated patients
with Philadelphia chromosome-positive (Ph+) leukemias
from 11 first- and second-line trials (pooled), newly diagnosed
CML patients treated with dasatinib or imatinib (DASISION),
and prostate cancer patients treated with dasatinib or placebo
plus docetaxel/prednisone (READY). Overall, 2–4% of
dasatinib-treated patients had cardiovascular ischemic events.
Most dasatinib-treated patients with an event had a history of
and/or risk factor for atherosclerosis (pooled 77 with history/
risk and event/96 with events; DASISION 8/10; READY 15/
18). Most cardiovascular ischemic events occurred within
1 year of initiating dasatinib (pooled 69/96; DASISION
7/10; READY 16/18). Comparison of observed and expected
event rates through standardized incidence ratios indicates that
dasatinib does not increase risk for cardiovascular ischemic
events compared with external reference populations.
Keywords Chronic myeloid leukemia . Tyrosine kinase
inhibitors . Dasatinib . Cardiovascular . Ischemic
Introduction
Treatment of chronic phase chronic myeloid leukemia (CML-
CP) with a BCR-ABL1-targeted tyrosine kinase inhibitor
(TKI) has transformed a once fatal disease into one that is
controlled in >90% of patients [1]. As most patients need to
continue lifelong therapy to maintain disease control, long-
term safety is becoming increasingly important to identify
potential new adverse events (AEs) that may arise during
extended treatment.
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Arterial ischemic events have emerged as AEs associated
with TKI therapy. Currently, four of the five BCR-ABL1 TKIs
approved for the treatment of CML (imatinib, dasatinib,
nilotinib, and ponatinib) have one or more AEs related to
arterial ischemia reported in the prescribing information;
however, the incidence of arterial ischemic events is lower
with imatinib and dasatinib compared with the incidence with
nilotinib and ponatinib [2–5]. Ponatinib was temporarily
withdrawn from the US market in 2014 due to patients
experiencing high rates of serious vascular AEs [6, 7], bring-
ing risk assessment of cardiovascular events to the forefront
for patients prescribed BCR-ABL1 TKIs.
The type and severity of ischemic events vary across the
TKIs. Dasatinib has been associated with pulmonary arterial
hypertension (PAH) [4], but the mechanism and any factors
potentially related to development of PAH are unknown.
Dasatinib should be discontinued in patients with documented
PAH, which then typically leads to partial or complete reversal
of the condition [4]. A strong association between nilotinib
and multiple vascular AEs (femoral artery stenosis, coronary
artery stenosis, intermittent claudication, and peripheral arte-
rial disease [PAD]) was identified through an analysis of data
from the FDA Adverse Event Reporting System (FAERS)
database [8]. Also, in the 5-year report of the Evaluating
Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, 8 and 13% of patients
who received 300 or 400 mg nilotinib, respectively, experi-
enced some form of cardiovascular event, including ischemic
heart disease, an ischemic cerebrovascular event, or PAD [9].
In patients with CML, phase I and II clinical trials investigat-
ing the use of ponatinib reported serious vascular events in
approximately 48 and 24% of patients, respectively [6, 7].
Recently, two separate groups have performed a meta-
analysis investigating the potential association of the currently
available BCR-ABL1 TKIs with vascular AEs. Findings from
Chai et al. concluded that patients who received nilotinib or
ponatinib experienced a greater number of major arterial
events than patients who received imatinib, dasatinib, or
non-TKI-based treatment [10]. Douxfils et al. analyzed
the incidence of vascular occlusive events in patients with
CML taking one of the five approved BCR-ABL1 TKIs.
Their overall conclusions were that there is an increased
risk of vascular occlusive events with all new-generation
TKIs compared with imatinib [11]. Retrospective meta-
analysis, however, is limited in its ability to draw conclu-
sions due to potential inconsistency among studies in
definitions of vascular AEs as well as variations in study
selection methods, duration of patient follow-up across
datasets, and inclusion and exclusion criteria. The analysis
presented here will focus on a broader set of clinical trial
data within the dasatinib trial program to gain a better and
deeper understanding of cardiovascular event rates in
dasatinib-treated patients.
After a 5-year follow-up of the phase III DASatinib versus
Imatinib Study In treatment-Naïve CML patients
(DASISION) study, 4% of dasatinib-treated patients experi-
enced a cardiovascular ischemic event compared with 2% of
imatinib-treated patients [12]. Therefore, we evaluated the oc-
currence of cardiovascular ischemic events across the
dasatinib clinical trial program. Cardiovascular ischemic
events were assessed for dasatinib-treated patients with
Philadelphia chromosome-positive (Ph+) leukemias in a
pooled population of 11 trials and for patients in the
dasatinib and non-dasatinib comparator arms from both
DASISION and a phase III trial in patients with prostate
cancer (READY). To determine whether the frequency of
these events in clinical trials is similar to the expected inci-
dence in similar populations from the community setting, the
expected rate of occurrence of cardiovascular ischemic events
was estimated in external reference populations generated
from an insurance claims database. Using standardized inci-
dence ratios (SIRs), these estimates were then compared with
the rate of occurrence of cardiovascular ischemic events in the
dasatinib clinical trial program.
Methods
Patient populations
Three dasatinib clinical trial populations were investigated
(Table 1): a large, pooled population of Ph+ dasatinib-treated
patients, including those from DASISION; dasatinib- and
imatinib-treated patients from the randomized phase III
DASISION trial [13]; and patients treated with dasatinib or
placebo plus docetaxel/prednisone from the randomized phase
III READY prostate cancer trial [14] (see Online Resource
Table S1).
Eligibility criteria and patient characteristics have been
described [12–23]. Patients in the pooled Ph+ population
had CML-CP (n = 1618) or advanced disease (CML in
accelerated/blast phase [CML-AP/BP] or Ph+ acute lympho-
blastic leukemia [Ph+ ALL]; n = 1094). They were treated
with first- or second-line dasatinib 15 to 240 mg daily in one
of 11 phase I/II/III clinical trials. All procedures followedwere
in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national) and with the Helsinki Declaration of 1975, as revised
in 2000–2008. Informed consent was obtained from all pa-
tients for being included in the study.
Data from a large, population-based US health insurance
claims database, MarketScan® Commercial Claims and
Medicare Supplemental (Truven Health Analytics, Ann
Arbor, MI, USA), from 2008 to 2013, were used to generate
the external reference populations (see Online Resource
Methods). Inclusion dates were based on available licensed
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data. The external reference populations included disease-
based populations of patients with CML and prostate cancer,
as well as general populations of all eligible patients and men
only (Table 1).
Analyses
Cardiovascular ischemic events evaluated in the dasatinib
clinical trials were identified using preferred terms from the
Medical Dictionary for Regulatory Activities (MedDRA) [24]
(see Online Resource Methods). Preexisting risk of cardiovas-
cular ischemic events was evaluated in the clinical trial patient
subsets with and without a cardiovascular ischemic event on
the basis of risk factors provided at enrollment, including
factors listed in Online Resource Methods.
Follow-up in all external reference populations occurred in
parallel with trial populations. Cases of cardiovascular ische-
mic events were defined by at least two instances of a
MedDRA preferred term code during the follow-up period.
Patients with the code identified before the follow-up period
were excluded from analysis in an attempt to mimic entry
criteria for the dasatinib clinical trials.
SIRs were calculated to evaluate observed incidence rates
of cardiovascular ischemic events in dasatinib clinical trials
compared with the expected incidence based on rates in an
external reference population. Expected rates were calculated
for each age and sex stratum and were summed to provide an
overall expected incidence rate in the dasatinib-treated popu-
lation. The observed rate in dasatinib-treated patients in the
clinical trial populations was then divided by the expected rate
in the appropriate reference population to determine the SIR
and a 95% confidence interval (CI). Calculations were
performed for the dasatinib clinical trials compared with both
appropriate external disease-based and general populations.
Specifically, patients from the pooled Ph+ population (all
2712 patients with CML-CP, CML-AP/BP, and Ph+ ALL)
and DASISION were compared with the general and CML
external reference populations, and patients from READY
were compared with the general male and prostate cancer
external reference populations.
Results
Incidence and timing of cardiovascular ischemic events
in dasatinib clinical trials
Characteristics of patients from dasatinib clinical trials and the
external reference populations are described in Table 1. There
were similar numbers of men and women in the clinical trials
and the external general and CML reference populations.
Median age was similar in READY and the external prostate
cancer reference population, but these were both higher
compared with the other clinical trial and external reference
populations. The external general population had the lowest
median age. Median duration of dasatinib therapy was
19 months for the pooled Ph+ population (29.0 months for
CML-CP and 6.2 months for CML-AP/BP/Ph+ ALL),
60 months for both arms of DASISION, and 8 months for
both arms of READY.
In all three dasatinib clinical trial populations, the incidence
of any cardiovascular ischemic event (defined in Online
Resource Methods) ranged from 2 to 4% (Table 2). In the
pooled Ph+ population, 55 (2%) patients had cardiovascular
ischemic events that were grade 3/4, and five (<1%) patients
died due to a cardiovascular ischemic event. Dasatinib dose
and CML disease phase do not appear to be associated with
increased risk of these events in the pooled Ph+ population
because event incidence was similar for patients with chronic
or advanced CML at different doses of dasatinib. In
DASISION, a total of 10 dasatinib-treated patients (4%)
experienced cardiovascular ischemic events compared with
Table 1 Dasatinib clinical trial and external reference populations
Men
(%)
Median age
(years)
Median duration of therapy
(months (range))
Pooled Ph+ population (N = 2712) Dasatinib 100–140 mg daily 53 54 19.2 (0–93.2)
DASISION (N = 519) Dasatinib 100 mg QD (n = 259) 56 46 60.5 (<0.1–72.7)
Imatinib 400 mg QD (n = 260) 63 49 60.3 (0.3–74.6)
READY (N = 1522) Dasatinib 100 mg QD + docetaxel/prednisone
(n = 762)
100 69 8.1 (0.1–41.4)
Placebo + docetaxel/prednisone (n = 760) 100 68 8.4 (<0.1–41.3)
External disease-based populations
(US claims database)
CML (N = 16,000) 56 59 –
Prostate cancer (N = 530,000) 100 66 –
External general populations
(US claims database)
General (N = 116,000,000) 48 42 –
General male (N = 56,000,000) 100 42 –
CML chronic myeloid leukemia, Ph+ Philadelphia chromosome-positive, QD once daily
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four patients (2%) who received imatinib (Table 2). Of the re-
ported events, five were grade 3/4 with dasatinib and two were
grade 3/4 with imatinib. In READY, 18 patients (2%) receiving
dasatinib experienced cardiovascular ischemic events compared
with nine patients (1%) given placebo (Table 2). Ten cardiovas-
cular ischemic events with dasatinib were grade 3/4 and six
events with placebo were grade 3/4. The most distinguishing
event between arms was myocardial infarction, where seven
(1%) and one (<1%) patients experienced this event in the
dasatinib and placebo arms, respectively.
Any history of and/or risk factors for atherosclerosis were
also taken into account in this assessment of cardiovascular
ischemic events. In the pooled Ph+ population, 47% of pa-
tients had a prior history of and/or had risk factors for
atherosclerosis (Table 3). The particular preexisting conditions
and risk factors identified are detailed in Table 3. Of the 96
cardiovascular ischemic events in the pooled Ph+ population,
77 (80%) were reported in these patients with a history of and/
or risk factors for atherosclerosis. The incidence of cardiovas-
cular ischemic events in the population with known risk
factors was 6% compared with 1% in those without reported
risk factors. In DASISION, 40 and 46% of patients had a
history of and/or risk factors for atherosclerosis in the
dasatinib and imatinib arms, respectively. The majority of
events in both arms were reported among patients with a his-
tory and/or risk factors for atherosclerosis: eight of 10 (80%)
cardiovascular ischemic events with dasatinib and three of
four (75%) with imatinib. A majority of patients from
Table 2 Cardiovascular ischemic events
Dasatinib-treated patients from pooled Ph+ population, n (%)
CML-CP CML-AP/BP or Ph+ ALL Ph+ leukemias (N = 2712)
100 mg QD (n = 548) All (n = 1618) 140 mg QD
(n = 304)
All (n = 1094)
Any CV ischemic eventa 17 (3.10) 65 (4.02) 6 (1.97) 31 (2.83) 96 (3.54)
MI 9 (1.64) 21 (1.30) 2 (0.66) 12 (1.10) 33 (1.22)
Angina pectoris 5 (0.91) 31 (1.92) 2 (0.66) 14 (1.28) 45 (1.66)
CAD 3 (0.55) 11 (0.68) 0 0 11 (0.41)
Otherb 1 (0.18) 10 (0.62) 3 (0.99) 10 (0.91) 20 (0.74)
Treated patients from DASISION, n (%)
Dasatinib 100 mg QD (n = 258) Imatinib 400 mg QD (n = 258)
Any grade Grade 3/4 Grade 5 Any grade Grade 3/4 Grade 5
Any CV ischemic eventa 10 (3.88) 5 (1.94) 2 (0.78) 4 (1.55) 2 (0.78) 1 (0.39)
MI 6 (2.33) 4 (1.55) 2 (0.78) 2 (0.78) 1 (0.39) 1 (0.39)
Angina pectoris 3 (1.16) 1 (0.39) 0 2 (0.78) 0 0
CAD 1 (0.39) 0 0 0 0 0
Acute coronary syndrome 0 0 0 1 (0.39) 1 (0.39) 0
Treated patients from READY, n (%)
Dasatinib 100 mg QD + docetaxel/prednisone
(n = 761)
Placebo + docetaxel/prednisone (n = 757)
Any grade Grade 3/4 Any grade Grade 3/4
Any CV ischemic eventa 18 (2.37) 10 (1.31) 9 (1.19) 6 (0.79)
MI 7 (0.92) 6 (0.79) 1 (0.13) 1 (0.13)
Angina pectoris 7 (0.92) 1 (0.13) 6 (0.79) 3 (0.40)
Myocardial ischemia 3 (0.39) 1 (0.13) 3 (0.40) 2 (0.26)
Troponin increasedc 2 (0.26) 1 (0.13) 1 (0.13) 0
CAD 1 (0.13) 0 1 (0.13) 1 (0.13)
Acute coronary syndrome 1 (0.13) 1 (0.13) 1 (0.13) 1 (0.13)
Coronary artery occlusion 1 (0.13) 1 (0.13) 0 0
ALL acute lymphoblastic leukemia, AP/BP accelerated/blast phase,CAD coronary artery disease,CML chronic myeloid leukemia,CP chronic phase,CV
cardiovascular, MI myocardial infarction, Ph+ Philadelphia chromosome-positive, QD once daily
a Patients may have had more than one event within a class
b Includes acute coronary syndrome, electrocardiogramT-wave abnormal, troponin I, troponin I increased, troponin increased, troponin T, and troponin T
increased
c Includes troponin I increased and troponin T increased
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READY, 66% of patients on dasatinib and 64% of patients on
placebo, had a history of and/or risk factors for atherosclerosis
(Table 3). Of the 18 dasatinib-treated patients with a cardio-
vascular ischemic event in the READY trial, 15 (83%) had a
history of and/or risk factors for atherosclerosis along with six
of nine (67%) patients in the placebo population.
The incidence of cardiovascular ischemic events increased
with age in the patients with CML in the pooled Ph+ population
and in DASISION. Of those aged ≤44 years, 1 and 2% from the
pooled Ph+ population and DASISION, respectively, experi-
enced an event compared with ≥10% in patients aged ≥75 years
(Table 4). No increase in cardiovascular ischemic events with
age was observed in patients from the READY study.
Most of the cardiovascular ischemic events in all three clinical
trial populations occurred within the first year of initiating
dasatinib, the majority within the first 6 months. In the pooled
Ph+ population, 69 of 96 events (72%) occurred during the first
year of dasatinib therapy (Table 5), with 57 occurring in the first
6 months and only 27 after 1 year. Seven of 10 events (70%)
from DASISION and 16 of 18 events (89%) from READYalso
occurred during the first year of treatment.After the first 6months
of treatment, the incidence of cardiovascular ischemic events was
similar for the dasatinib and comparator arms in both trials, and
overall, there was no increase in ischemic events with exposure
to dasatinib over time. The incidence in at-risk patients was cal-
culated after the first year of treatment, taking into account those
patients who had already experienced an on-study cardiovascular
ischemic event (Table 5). Incidence for the pooled Ph+ popula-
tion and in DASISIONwas 3% in the first year and decreased to
0 to 1% in at-risk populations in subsequent years.
Due to the varying follow-up times and numbers of patients
enrolled across these trials, incidence rates of cardiovascular
ischemic events based on patient-years of dasatinib exposure
were determined. Incidence in the pooled population was 1.5
events/100 patient-years. Rates were 0.9 and 0.4 events/100
patient-years for the dasatinib and imatinib arms, respectively,
in DASISION. Dasatinib- and placebo-treated patients from
the READY trial were calculated to have had 3.0 and 1.4
events/100 patient-years, respectively.
Standardized incidence ratios
In this analysis, a SIR 95% CI range that does not fall across a
value of 1.0 indicates that the incidence of the event in clinical
Table 3 Baseline history of and/or risk factors for atherosclerosis
Treated patients, n (%)
Pooled Ph+
population
(N = 2712)
DASISION READY
Dasatinib 100 mg QD
(n = 258)
Imatinib 400 mg QD
(n = 258)
Dasatinib 100 mg QD
+ docetaxel/prednisone
(n = 761)
Placebo + docetaxel/
prednisone (n = 757)
History of and/or risk factor for atherosclerosisa
Yes 1280 (47.20) 104 (40.31) 119 (46.12) 504 (66.23) 483 (63.80)
CV ischemic events 77 (6.02) 8 (7.69) 3 (2.52) 15 (2.98) 6 (1.24)
No CV ischemic
events
1203 (93.98) 96 (92.31) 116 (97.48) 489 (97.02) 477 (98.76)
No 1432 (52.80) 154 (59.69) 139 (53.88) 257 (33.77) 274 (36.20)
CV ischemic events 19 (1.33) 2 (1.30) 1 (0.72) 3 (1.17) 3 (1.09)
No CV ischemic
events
1413 (98.67) 152 (98.70) 138 (99.28) 254 (98.83) 271 (98.91)
History of atherosclerosis
Preexisting IHD 165 (6.08) 9 (3.49) 13 (5.04) 106 (13.93) 98 (12.95)
Preexisting non-cardiac
atherosclerosis
104 (3.83) 10 (3.88) 10 (3.88) 44 (5.78) 48 (6.34)
Risk factors for atherosclerosisb
Current smoker 242 (8.92) 31 (12.02) 50 (19.38) 39 (5.12) 36 (4.76)
Former smoker 401 (14.79) 23 (8.91) 20 (7.75) 50 (6.57) 55 (7.27)
Hypertension 625 (23.05) 47 (18.22) 43 (16.67) 370 (48.62) 346 (45.71)
Diabetes 245 (9.03) 19 (7.36) 13 (5.04) 116 (15.24) 131 (17.31)
Hypercholesterolemia 216 (7.96) 25 (9.69) 23 (8.91) 168 (22.08) 161 (21.27)
CV cardiovascular, IHD ischemic heart disease, Ph+ Philadelphia chromosome-positive, QD once daily
a Patients may have had both a history of and risk factors for atherosclerosis
b Patients may have had more than one risk factor
Ann Hematol (2017) 96:1303–1313 1307
trials is statistically different than expected based on compar-
ison to the reference population. Based on the SIRs, the
overall rates of cardiovascular ischemic events observed in
dasatinib-treated patients from the pooled Ph+ population
were not higher than expected when compared with the exter-
nal CML and general populations (Fig. 1). Acute myocardial
infarction occurred at a higher rate than expected (SIR >1.0),
but the differences relative to external reference populations
were not statistically significant (95% CI included 1.0).
Similarly, using SIRs, cardiovascular ischemic event rates in
either treatment arm of DASISION were not higher than
expected when compared with the external reference popula-
tions, except for acute myocardial infarction (Fig. 1).
However, as in the pooled Ph+ population, this difference
was not significant. All cardiovascular ischemic events were
reported less often than expected in both dasatinib- and
placebo-treated patients in the READY study (Fig. 2).
Discussion
Arterial ischemic events have been reported in association
with TKI use in patients with CML [2–5]. In this analysis,
cardiovascular ischemic events were investigated in pa-
tients from dasatinib clinical trials that enrolled patients
with Ph+ leukemia and prostate cancer and found that a
low percentage (2–4%) experienced an event while re-
ceiving dasatinib. The highest cardiovascular ischemic
event incidence rate per 100 patient-years observed in this
analysis was for dasatinib-treated patients in the READY
study (3.0/100 patient-years). This was higher than the
rate for placebo-treated patients in the READY study
(1.4/100 patient-years), dasatinib-treated patients in
DASISION (0.9/100 patient-years), and patients in the
pooled population treated with dasatinib (1.5/100 pa-
tient-years). Most cardiovascular events occurred in the
first year of dasatinib treatment, supporting lack of a
cumulative drug effect, although additional studies are
required to help determine whether there is an acute pro-
cess for the development of these events early after initi-
ation of therapy.
SIRs analysis demonstrated that cardiovascular ischemic
event rates in dasatinib-treated patients in clinical trials were
not higher than would be expected relative to comparable ex-
ternal populations. This finding is consistent with the results
from the FAERS analysis, which also did not show an associ-
ation between dasatinib and cardiovascular ischemic events [8].
The list of cardiovascular ischemic events used in the
analysis presented here did not include peripheral or
cerebrovascular ischemic events. A retrospective analysis
specifically examining reports of PAD/PAD-related
events, which included the 11 clinical trials that composed
the pooled Ph+ population here, reported a cumulative
event incidence of 0.4% (11/2712) for dasatinib-treated
patients [25]. Also, within the pooled Ph+ population,
30 of 2712 patients (1%) reported a cerebrovascular
event. With this low incidence of PAD and cerebrovascu-
lar ischemic events, it is likely that inclusion of them in
this analysis of cardiovascular ischemic event incidence
would not alter the overall interpretation of the results.
Table 4 Cardiovascular ischemic events by age
Dasatinib-treated patients from the pooled Ph+ population, n (%)
Total ≤44 years 45–64 years 65–74 years ≥75 years
Total patients 2712 (100) 835 (30.79) 1260 (46.46) 494 (18.22) 123 (4.54)
CV ischemic event 96 (3.54) 9 (1.08) 44 (3.49) 31 (6.28) 12 (9.76)
No CV ischemic event 2616 (96.46) 826 (98.92) 1216 (96.51) 463 (93.72) 111 (90.24)
Treated patients from DASISION, n (%)
Dasatinib 100 mg QD Imatinib 400 mg QD
Total ≤44 years 45–64 years 65–74 years ≥75 years Total
Total patients 258 (100) 120 (46.51) 113 (43.80) 18 (6.98) 7 (2.71) 258 (100)
CV ischemic event 10 (3.88) 2 (1.67) 5 (4.42) 1 (5.56) 2 (28.57) 4 (1.55)
No CV ischemic event 248 (96.12) 118 (98.33) 108 (95.58) 17 (94.44) 5 (71.43) 254 (98.45)
Treated patients from READY, n (%)
Dasatinib 100 mg QD + docetaxel/prednisone Placebo + docetaxel/prednisone
Total ≤44 years 45–64 years 65–74 years ≥75 years Total
Total patients 761 (100) N/A 251 (32.98) 333 (43.76) 177 (23.26) 757 (100)
CV ischemic event 18 (2.37) N/A 4 (1.59) 10 (3.00) 4 (2.26) 9 (1.19)
No CV ischemic event 743 (97.63) N/A 247 (98.41) 323 (97.00) 173 (97.74) 748 (98.81)
CV cardiovascular, N/A not applicable, Ph+ Philadelphia chromosome-positive, QD once daily
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The phase III DASISION and READY trials each had a
comparator arm that did not receive dasatinib and was adminis-
tered either imatinib or placebo, respectively. With the overall
low incidence and the lack of a significant difference among
treatment arms in comparative trials, we cannot conclude that
dasatinib confers a greater risk for vascular ischemia.
There are some data indicating that nilotinib and ponatinib
may confer a greater risk for vascular ischemic events than
imatinib and dasatinib [2–5]; however, cross-trial comparisons
are difficult due to varying reporting requirements, enrollment
criteria, and the choice of terms used to define a cardiovascular
event from one trial to the next [26]. For example, in
DASISION, patients with a history of myocardial infarction
were only excluded if an event had occurred within the previ-
ous 6 months [13], whereas all patients with a history of myo-
cardial infarction were excluded in the ENESTnd study [27].
Regardless of the variations across the different TKI
studies, it is important to consider that both nilotinib and
ponatinib have been associated with development of vascular
ischemic events over time [7, 28]. In the 5-year follow-up to
the ENESTnd study, a cumulative increase in the frequency of
cardiovascular events was observed in nilotinib-treated patients
[9]; furthermore, the FAERS analysis reported a unique associa-
tion of peripheral and cardiac vascular events with nilotinib [8].
Response to ponatinib was investigated in patients with CML
previously treated with dasatinib or nilotinib or who had a BCR-
ABL1 T315I mutation, in the PACE study (n = 449) [29]. The
proportion of patients with vascular ischemic events on ponatinib
increased from 9 to 17% from 11 to 24 months of follow-up [7].
While higher doses of nilotinib or ponatinib have been associated
with increased vascular ischemic events [6], neither dasatinib
dose nor disease phase affected the frequency of cardiovascular
ischemic events in this analysis. The varied effect that the differ-
ent BCR-ABL1 TKIs have on development of cardiovascular
AEs should be considered in future studies as an opportunity to
examine physiologic targets of TKIs to gain a better understand-
ing of arterial ischemic events in general.
The relation between risk factors for experiencing a cardio-
vascular ischemic event (preexisting ischemic heart disease
and non-cardiac atherosclerosis, smoking, hypertension,
Table 5 Time to first cardiovascular event by age
Timing of first CV
ischemic event
Dasatinib-treated patients from pooled Ph+ population, n (%)
Total
(N = 2712)
≤44 years
(n = 835)
45–64 years
(n = 1260)
65–74 years
(n = 494)
≥75 years
(n = 123)
Patients with
event/at risk
0 to <6 months 57 (2.10) 6 (0.72) 25 (1.98) 20 (4.05) 6 (4.88) 69/2712 (2.54)
6 to <12 months 12 (0.44) 0 6 (0.48) 4 (0.81) 2 (1.63)
1 to <2 years 11 (0.41) 1 (0.12) 5 (0.40) 4 (0.81) 1 (0.81) 11/1617 (0.68)
2 to <3 years 5 (0.18) 1 (0.12) 3 (0.24) 0 1 (0.81) 5/1202 (0.42)
3 to <4 years 5 (0.18) 0 3 (0.24) 2 (0.40) 0 5/847 (0.59)
4 to <7 years 6 (0.22) 1 (0.12) 2 (0.16) 1 (0.20) 2 (1.63) 6/696 (0.86)
Treated patients from DASISION, n (%)
Dasatinib 100 mg QD Imatinib 400 mg QD
Timing of first CV
ischemic event
Total
(N = 258)
≤44 years
(n = 120)
45–64 years
(n = 113)
65–74 years
(n = 18)
≥75 years
(n = 7)
Patients with
event/at risk
Total
(N = 258)
0 to <6 months 4 (1.55) 1 (0.83) 2 (1.77) 1 (5.56) 0 7/258 (2.71) 0
6 to <12 months 3 (1.16) 0 2 (1.77) 0 1 (14.29) 1 (0.39)
1 to <2 years 0 0 0 0 0 0/227 0
2 to <3 years 2 (0.78) 0 1 (0.88) 0 1 (14.29) 2/207 (0.97) 2 (0.78)
3 to <6 years 1 (0.39) 1 (0.83) 0 0 0 1/185 (0.54) 1 (0.39)
Treated patients from READY, n (%)
Dasatinib 100 mg QD + docetaxel/prednisone Placebo +
docetaxel/prednisone
Timing of first CV
ischemic event
Total
(N = 761)
≤44 years 45–64 years
(n = 251)
65–74 years
(n = 333)
≥75 years
(n = 177)
Patients with
event/at risk
Total
(N = 757)
0 to <6 months 14 (1.84) N/A 1 (0.40) 9 (2.70) 4 (2.26) 16/761 (2.10) 7 (0.92)
6 to <12 months 2 (0.26) N/A 1 (0.40) 1 (0.30) 0 2 (0.26)
1 to <2 years 2 (0.26) N/A 2 (0.80) 0 0 2/255 (0.78) 0
2 to <6 years 0 N/A 0 0 0 0 0
CV cardiovascular, N/A not applicable, Ph+ Philadelphia chromosome-positive, QD once daily
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diabetes, and hypercholesterolemia) and event incidence was
also investigated in this analysis. Approximately 80% of the
cardiovascular ischemic events reported in patients receiving
dasatinib occurred in patients who had a history of and/or risk
factors for atherosclerosis. The ENESTnd study also reported
a higher incidence of cardiovascular events in nilotinib-treated
Any CV event
Myocardial ischemic events
Angina unstable
Angina pectoris
Acute myocardial infarction
Any CV event
Myocardial ischemic events
Angina unstable
Angina pectoris
Acute myocardial infarction
External CML Population
External General Population
External CML Population
External General Population
External CML Population
External General Population
Pooled Ph+ Population 
vs Comparators
DASISION: Dasatinib 100 mg QD
vs Comparators 
DASISION: Imatinib 400 mg QD
vs Comparators 
CV Event Rate: Imatinib <
Comparator
Imatinib >
Comparator 
Dasatinib <
Comparator
Dasatinib >
Comparator 
Pooled <
Comparator
Pooled >
Comparator 
SIR (95% Confidence Interval) SIR (95% Confidence Interval) SIR (95% Confidence Interval)
-0.5 0.5 1.5 2.5 3.5 4.5 -0.5 0.5 1.5 2.5 3.5 4.5 -0.5 0.5 1.5 2.5 3.5 4.5
Fig. 1 Standardized incidence ratios of cardiovascular ischemic event
rates among patients from the pooled Ph+ population and DASISION
and external reference populations. Standardized incidence ratios (SIRs;
diamonds) were calculated for the pooled Ph+ population and patients in
the dasatinib and imatinib arms of DASISION. Observed CVevent values
from the study analysis were compared to expected values in both an
external CML population and a general population, and 95%
confidence intervals (CIs; horizontal bars) were calculated. The vertical
line denotes a SIR of 1.0. If a SIR 95% CI range includes the value of 1.0,
it is suggested that the event occurred as expected. If the SIR 95% CI is
<1.0, it is suggested that the event occurred less frequently than expected
and if it is >1, more frequently than expected. Any CV event includes
myocardial ischemic events (including electrocardiogram signs of
myocardial ischemia), angina unstable (including acute coronary
syndrome, coronary artery occlusion, and troponin I increased), angina
pectoris, acute myocardial infarction (including troponin I, silent MI, and
MI), arteriosclerosis coronary artery, coronary artery disease, troponin T,
troponin T increased, electrocardiogram T-wave abnormal, and coronary
arterial stent insertion. CML chronic myeloid leukemia, CV
cardiovascular, Ph+ Philadelphia chromosome-positive, QD once daily
External Prostate Cancer Population
-0.5 0.5 1.5 2.5 3.5 4.5
SIR (95% Confidence Interval)
External Prostate Cancer Population
READY: Dasatinib 100 mg QD +
Docetaxel/Prednisone vs Comparator
READY: Placebo +
Docetaxel/Prednisone vs Comparator
Any CV event
Myocardial ischemic events
Angina unstable
Angina pectoris
Acute myocardial infarction
Any CV event
Myocardial ischemic events
Angina unstable
Angina pectoris
Acute myocardial infarction
SIR (95% Confidence Interval)
-0.5 0.5 1.5 2.5 3.5 4.5
CV Event Rate: Dasatinib <
Comparator
Dasatinib >
Comparator
External General Male Population
Placebo <
Comparator
Placebo >
Comparator
External General Male Population
Fig. 2 Standardized incidence ratios of cardiovascular ischemic event
rates among patients from READY and external reference populations.
Standardized incidence ratios (SIRs; diamonds) were calculated for
patients in the dasatinib and placebo arms of the READY trial.
Observed CV event values from the READY trial were compared to the
expected number of events from both an external prostate cancer
population and a general male population, and 95% confidence
intervals (CIs; horizontal bars) were calculated. The vertical line
denotes a SIR of 1.0. If a SIR 95% CI range includes the value of 1.0,
it is suggested that the event occurred as expected. If the SIR 95% CI is
<1, it is suggested that the event occurred less than expected and if it is >1,
more than expected. Any CVevent includes myocardial ischemic events
(including electrocardiogram signs of myocardial ischemia), angina
unstable (including acute coronary syndrome, coronary artery
occlusion, and troponin I increased), angina pectoris, acute myocardial
infarction (including troponin I, silent MI, and MI), arteriosclerosis
coronary artery, coronary artery disease, troponin T, troponin T
increased, electrocardiogram T- wave abnormal, and coronary arterial
stent insertion. CV cardiovascular, QD once daily
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patients with high versus low cardiovascular risk scores [9].
Furthermore, the likelihood of experiencing an arterial throm-
botic event was reported to be associated with cardiovascular
risk in ponatinib-treated patients in the PACE trial [30]. Aging
is also associated with an increased incidence of cardiovascular
disease, as 51% of US adults with cardiovascular disease are
aged ≥60 years [31]. In an observational study of patients with
CML-CP treated with first-line imatinib, dasatinib, or nilotinib
in the community setting (SIMPLICITY; NCT01244750),
cardiovascular event-related hospitalizations were higher in
older patients [32].
In this analysis, the percentage of patients with a cardiovas-
cular ischemic event, when treated with dasatinib, in the
pooled Ph+ population and DASISION increased with age.
Despite the increased age of patients from READY, the rate of
events in both arms of this study did not exceed the rates in the
studies of patients with Ph+ leukemia or what was expected
when compared to age- and sex-adjusted cohorts used for the
SIRs. The reasons are unclear why there is not a more defined
relationship between occurrence of cardiovascular ischemic
events and age in READY. The READY study did not include
a population of patients who were <44 years of age (31 and
47% of the pooled and DASISION populations, respectively),
which could possibly make identifying an association
between events and age difficult. The median daily dose of
dasatinib for patients in READY was 99 mg, which is
comparable to the medians of 88 mg received by patients with
CML-CP and 125 mg received by patients with CML-AP/BP
or Ph+ ALL in the pooled population; this suggests that dos-
age differences do not account for the lack of age-associated
cardiovascular events in patients from READY. One possibil-
ity is that the presence of concomitant medications, such as
docetaxel and/or prednisone, may have altered the risk.
Another explanation may be the previous androgen dep-
rivation therapy (ADT) received by the READY popula-
tion. There is evidence that ADT may be associated with
cardiotoxicity and that related AEs are more common in
patients with preexisting cardiovascular comorbidities
[33]. Therefore, if the risk of experiencing a cardiovascu-
lar event was already increased in the READY population
due to ADT, any effect of age on these events in patients
who did or did not receive dasatinib may be more difficult
to observe.
There are limitations to the SIR analysis owing to dif-
ferences in data collection between international clinical
trials and US insurance claims populations. Some cardio-
vascular ischemic events identified in clinical trials were
not identified in the MarketScan database, potentially be-
cause the terminology may not be equivalent to what was
reported in clinical trials. Also, reporting of AEs in the
MarketScan database was voluntary, so the incidence of car-
diovascular ischemic events is most likely underestimated.
The clinical trial populations also differed from the general
population due to inclusion/exclusion criteria, concomitant
medications, performance status, and organ function of pa-
tients based on clinical trial eligibility criteria, which cannot
be controlled for in the external reference populations.
In summary, in this analysis of a large population of
patients who received dasatinib across a clinical trial
program, a low proportion of patients experienced cardio-
vascular ischemic events across all of the doses tested.
Moreover, the rates of cardiovascular ischemic events
were not higher than expected when compared with
CML or prostate cancer populations from publicly avail-
able databases in the USA, after adjusting for age and sex.
Among patients who experienced a cardiovascular ische-
mic event, the majority had a history of prior arterial
ischemic events or risk factors for atherosclerosis. In
contrast to what has been observed with other TKIs,
events were largely restricted to within the first year after
initiation of dasatinib, with no evidence of a cumulative
risk. Physicians should carefully assess preexisting co-
morbidities and risk factors when selecting treatment for
patients with Ph+ leukemia and should monitor patients
closely during therapy.
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